World Hepatitis Alliance submits written intervention ahead of 73rd World Health Assembly

The 73rd World Health Assembly took place virtually on Monday 18 and Tuesday 19 May. WHA submitted a written intervention, which drew on findings from our global COVID-19 survey, to highlight the impact of COVID-19 on people living with viral hepatitis and on hepatitis services. 

The statement is part of our continuous efforts to ensure that hepatitis remains firmly on the global health agenda. It urges Member States to seize the unprecedented opportunity presented by the current pandemic to make the most of synergies in screening opportunities and embed hepatitis elimination within evolving health systems. You can read the full intervention below:

The COVID-19 pandemic presents the biggest global health threat in a generation. Whilst the pandemic is affecting nearly everyone, it is having the greatest impact on the populations most undeserved by health systems. These same communities are disproportionately affected by viral hepatitis, a disease that claims more than 4,000 lives every day. The viral hepatitis community stands ready to play its part in tackling the COVID-19 pandemic to safeguard the lives of these at-risk and marginalised populations.

On the ground, hepatitis services are adapting to face the dual threats of COVID-19 and viral hepatitis, however, organisations need support from Member States to continue to deliver vital services at this time. The COVID-19 pandemic has severely disrupted hepatitis elimination programmes across the world. Research conducted by the World Hepatitis Alliance reveals only 10% of services are still functioning as normal. Without the availability of effective prevention, testing and treatment services, our hopes of eliminating hepatitis by 2030 are diminished, and thousands of people affected by viral hepatitis are left facing an uncertain future.

The mass testing of populations for COVID-19 by Member States offers an unprecedented opportunity to test people for viral hepatitis at the same time. 290 million people live with viral hepatitis unaware, because of this countless lives are lost from a disease we can prevent and treat. If we can find the missing millions living with hepatitis unaware and link them to care we can get on track to eliminate hepatitis by 2030. Member States who seize this opportunity will strengthen health systems; reduce the future costs of hepatitis care and save millions of lives.

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close